☆ 4.8 Article

Case Report: Interindividual variability and possible role of heterozygous variants in a family with deficiency of adenosine deaminase 2: are all heterozygous born equals?

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Cell Biology

T cells and monocytes: A dangerous liaison in adenosine deaminase 2 deficiency

Cristina Mesa-Nunez et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

Add to Collection

Article Immunology

The Spectrum of the Deficiency of Adenosine Deaminase 2: An Observational Analysis of a 60 Patient Cohort

Karyl S. Barron et al.

Summary: The deficiency of adenosine deaminase 2 (DADA2) is a wide-ranging disease with multiple systemic manifestations and overlapping phenotypes. This study provides a long-term follow-up of DADA2, highlighting the clinical heterogeneity and the potential for phenotypic evolution.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients

Francesca Schena et al.

Summary: DADA2 patients show decreased memory B cells, particularly in class switch memory, and an expansion of CD21(low)B cells. In vitro stimulated B lymphocytes can secrete nonfunctional ADA2 protein, suggesting a cell intrinsic defect leading to impaired B-cell proliferation and differentiation. Additionally, CD4(+) and CD8(+) T cells are reduced, while circulating T follicular helper cells are significantly increased but have impaired IL-21 production, potentially contributing to impaired B cell help.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

Add to Collection

Article Rheumatology

Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2)

Samantha Cooray et al.

Summary: Anti-TNF treatment significantly reduced the incidence of ischaemic events and other vasculitic manifestations of DADA2, but was not effective for immunodeficiency or bone marrow failure.

RHEUMATOLOGY (2021)

Add to Collection

Article Immunology

Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency

Jin Yan Yap et al.

Summary: The study conducted in-depth immunophenotyping and functional analysis of human lymphocytes in ten patients with DADA2, revealing defects in B cell differentiation, impaired memory T cell differentiation, and increased inflammatory monocytes and immature NK cells. The findings shed light on the complex immune phenotype of DADA2 and suggest the need for targeted therapy to prevent viral infections and excessive inflammation in these patients.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Rheumatology

Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment

Benzeeta Pinto et al.

Summary: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic disease caused by biallelic mutations in the ADA2 gene, resulting in a wide spectrum of clinical manifestations including vasculitis, autoinflammatory, immunological and hematological disorders. Treatment options currently include tumor necrosis factor inhibitors and hematopoietic stem cell transplantation. Further research is needed to fully understand the pathogenesis and clinical aspects of the disease for early diagnosis and prompt treatment.

CLINICAL RHEUMATOLOGY (2021)

Add to Collection

Article Immunology

Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients

Hasan Hashem et al.

Summary: HCT is an effective treatment for DADA2, successfully reversing refractory cytopenia, vasculopathy, and immunodeficiency. The 2-year survival rate is as high as 97%, with improvements in hematological and immunological phenotypes during follow-up.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Rheumatology

DADA2 diagnosed in adulthood versus childhood: A comparative study on 306 patients including a systematic literature review and 12 French cases

Antoine Fayand et al.

Summary: DADA2 diagnosed in adulthood more often presents with a vascular phenotype and less often with bone marrow failure compared to DADA2 diagnosed in childhood. Adults diagnosed with DADA2 vasculopathy exhibit more severe skin involvement but fewer strokes.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)

Add to Collection

Article Hematology

Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency

Matteo Zoccolillo et al.

Summary: DADA2 is a rare genetic disorder that can be treated with anti-tumor necrosis factor therapy and HSPC transplantation. Research has shown that genetic correction of HSPCs can effectively treat DADA2, with patients' re-expressing ADA2 HSPCs retaining differentiation potential.

BLOOD ADVANCES (2021)

Add to Collection

Article Rheumatology

A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2

Seza Ozen et al.

JOURNAL OF RHEUMATOLOGY (2020)

Add to Collection

Article Medical Laboratory Technology

ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era

Yael Shinar et al.

CLINICAL CHEMISTRY (2020)

Add to Collection

Article Immunology

Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance

Oskar Schnappauf et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Rheumatology

The Many Faces of a Monogenic Autoinflammatory Disease: Adenosine Deaminase 2 Deficiency

Jennifer Lee Kendall et al.

CURRENT RHEUMATOLOGY REPORTS (2020)

Add to Collection

Article Hematology

Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2

Carmelo Carmona-Rivera et al.

BLOOD (2019)

Add to Collection

Letter Medicine, General & Internal

Treatment Strategies for Deficiency of Adenosine Deaminase 2

Amanda K. Ombrello et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Rheumatology

Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency

Sezgin Sahin et al.

RHEUMATOLOGY INTERNATIONAL (2018)

Add to Collection

Article Biochemistry & Molecular Biology

A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience

Melanie Rama et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2018)

Add to Collection

Article Allergy

ADA2 deficiency: Clonal lymphoproliferation in a subset of patients

Luca Trotta et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)

Add to Collection

Review Immunology

Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment

Isabelle Meyts et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2018)

Add to Collection

Article Pediatrics

ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease

Erika Van Nieuwenhove et al.

PEDIATRICS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells

Yuliia Kaljas et al.

CELLULAR AND MOLECULAR LIFE SCIENCES (2017)

Add to Collection

Article Oncology

Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2

Hasan Hashem et al.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2017)

Add to Collection

Article Rheumatology

Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood

Johanna Schepp et al.

ARTHRITIS & RHEUMATOLOGY (2017)

Add to Collection

Article Rheumatology

ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study

Roberta Caorsi et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Article Rheumatology

Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations

Joris M. Van Montfrans et al.

RHEUMATOLOGY (2016)

Add to Collection

Article Rheumatology

Deficiency of Adenosine Deaminase Type 2 A Description of Phenotype and Genotype in Fifteen Cases

Sira Nanthapisal et al.

ARTHRITIS & RHEUMATOLOGY (2016)

Add to Collection

Article Genetics & Heredity

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards et al.

GENETICS IN MEDICINE (2015)

Add to Collection

Letter Rheumatology

A Case Series of Adenosine Deaminase 2-deficient Patients Emphasizing Treatment and Genotype-phenotype Correlations

Ezgi Deniz Batu et al.

JOURNAL OF RHEUMATOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Early- Onset Stroke and Vasculopathy Associated with Mutations in ADA2

Qing Zhou et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy

Paulina Navon Elkan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Basis for the Growth Factor Activity of Human Adenosine Deaminase ADA2

Anton V. Zavialov et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2010)

Add to Collection

Article Hematology

Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26

Holger K. Eltzschig et al.

BLOOD (2006)

Add to Collection

Article Biochemistry & Molecular Biology

Human plasma adenosine deaminase 2 is secreted by activated monocytes

S Iwaki-Egawa et al.

BIOLOGICAL CHEMISTRY (2006)

Add to Collection

Article Biochemistry & Molecular Biology

Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity

AV Zavialov et al.

BIOCHEMICAL JOURNAL (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.